BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 29464778)

  • 1. Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma.
    Davidson B; Holth A; Wang Z; Hellsylt E; Tropé CG; Hetland Falkenthal TE; Holm R
    APMIS; 2018 Apr; 126(4):309-313. PubMed ID: 29464778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
    Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
    Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma.
    Davidson B; Bjørnerem M; Holth A; Hellesylt E; Hetland Falkenthal TE; Flørenes VA
    Gynecol Oncol; 2018 Jul; 150(1):136-142. PubMed ID: 29804637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
    Vaksman O; Davidson B; Tropé C; Reich R
    Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble AXL is ubiquitously present in malignant serous effusions.
    Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
    Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
    Dos Santos MV; Holth A; Bischof K; Davidson B
    Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2021 Mar; 32(2):161-168. PubMed ID: 33025675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
    Chehover M; Reich R; Davidson B
    Virchows Arch; 2020 Aug; 477(2):249-258. PubMed ID: 31900634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.
    Davidson B; Holth A; Nguyen MT; Tropé CG; Wu C
    Gynecol Oncol; 2013 Feb; 128(2):364-70. PubMed ID: 23099104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
    Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.